8:30 am Digital Networking Room Opens
Cutting-Edge Claudin Development: Showcasing Development of Novel Claudin Therapies Revolutionizing Oncology
9:00 am Chair’s Opening Remarks
9:00 am Zolbetuximab: Clinical Development of Claudin 18.2 Monoclonal Antibodies (Recorded Presentation)
Synopsis
- Exploring Zolbetuximab, a monoclonal antibody targeting claudin 18.2, and its application in treating metastatic gastric cancer
- Reviewing a detailed presentation on clinical trial outcomes, including efficacy, safety, and the impact on progression-free survival and overall survival rates
- Integrating Zolbetuximab into standard treatment regimens and its potential for combination with other therapeutic modalities
9:30 am XmAb541, a Claudin 6-Targeted Bispecific Antibody Therapy for Targeting Solid Tumors
Synopsis
- Preclinical development of XmAb541, a CLDN6 x CD3 bispecific antibody for selective targeting of CLDN6 expressing tumors
10:00 am Virtual Introductions & Networking Session
Synopsis
During this session you will be divided into separate breakout rooms with you fellow Claudin speakers and attendees. This is your opportunity to introduce yourself to your Claudin peers, and debate the most pressing challenges and opportunities facing this emerging oncology target.
10:30 am Coffee Break
Clinical Modality Advancements & Biological Insights in Claudin-Targeted Cancer Therapies
11:00 am Panel Discussion: Clinical Advancements in Claudin-Targeted ADCs, Bispecifics, & CAR-T Therapies
Synopsis
- Deep diving into the latest advancements and clinical outcomes of ADCs targeting Claudin 18.2 and Claudin 6, with a focus on engineering, payload optimization, and toxicity management specific to claudin targets
- Examining the role and efficacy of bispecific antibodies in enhancing the immune response against claudin-expressing tumors, supported by insights from preclinical and clinical data
- Analyzing the development, challenges, and clinical trial results of CAR-T therapies for claudin-targeted treatments, emphasizing construct design, manufacturing hurdles, and strategies for managing associated toxicities
11:45 am Understanding the Synergistic Potential of Combining Claudin 18.2-Targeted Therapies with Immunotherapies
Synopsis
- Examining the rationale for combining Claudin 18.2-targeted therapies with immunotherapies, such as checkpoint inhibitors, to enhance anti-tumor immune responses
- Exploring preclinical and clinical data supporting combination strategies, focusing on the synergistic effects and improved therapeutic outcomes
- Reviewing the impact of combination therapies on efficacy and safety profiles, including strategies to manage immune-related adverse events
12:15 pm Lunch & Networking
Exploring Innovations & Applications in Claudin 6-Targeted Cancer Therapies
1:15 pm Identification & Preclinical Characterization of CTIM-76, a CLDN6 x CD3 Bispecific Antibody
Synopsis
- Isolation of CLDN6 antibodies with exquisite specificity for CLDN6 over other members of the CLDN family
- Molecular engineering and in vitro characterization of CTIM-76
- Preclinical data supporting CTIM-76 entry into clinical trials for ovarian cancer and other advanced solid tumors
1:45 pm Development & Application of Claudin 6-Targeted Therapies in Ovarian, Testicular, & Endometrial Cancers
Synopsis
- Focusing on Claudin 6 expression in ovarian, testicular, and endometrial cancers and the potential for targeted therapies in these indications
- Uncovering the development and clinical potential of ADCs targeting Claudin 6, including preclinical efficacy and safety data
- Highlighting the safety profile and patient selection criteria for Claudin 6-targeted therapies, including strategies to minimize off-target effects
2:15 pm Claudin 1: in Cancer & Organ Fibrosis
Synopsis
- Examining the role of Claudin 1 in cancer and organ fibrosis
- Discussing the pre-clinical development and the therapeutic potential of monoclonal antibodies and ADCs targeting Claudin 1
- Addressing the phase I development for Claudin 1-targeted therapies